Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

35.17 +0.58 (+1.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Where Ultragenyx Pharmaceutical Stands With Analysts
 
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Preview: Ultragenyx Pharmaceutical
 
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
 
Via Benzinga
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
 
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
 
Via Benzinga
Where Ultragenyx Pharmaceutical Stands With Analysts
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: 
Via Benzinga
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at Piper Sandler Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx Announces Departure of Chief Financial Officer
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Ultragenyx to Present at Upcoming Healthcare Conferences
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 283 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Upgrades 
Via Benzinga
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
9 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Earnings Scheduled For November 2, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 265 companies made new 52-week lows. 
Via Benzinga
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
Gainers 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.